C5 — Drug Target

All drugs that target C5 — marketed and clinical-stage. Includes 4 drug classes acting on this target.

Drug classes

Complement Inhibitor [EPC] · Monoclonal antibody · Complement C5 inhibitor · Complement inhibitor

Marketed (2)

• VEOPOZ · REGENERON PHARMACEUTICALS · Complement Inhibitor [EPC] · Other
  Pozelimab-bbfg blocks C5 cleavage, preventing C5a and C5b formation and inhibiting terminal complement activation.
• H5G1.1 · AstraZeneca · Complement Inhibitor [EPC] · Neuroscience
  Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation.

Phase 3 pipeline (2)

• Soliris (eculizumab) · Samsung Bioepis Co., Ltd. · Monoclonal antibody · Immunology
  Soliris works by inhibiting the complement system by blocking the action of C5.
• C5 Inhibitor · Alexion Pharmaceuticals, Inc. · Complement C5 inhibitor · Immunology
  A C5 complement inhibitor blocks the activation of the C5 component of the complement cascade, preventing formation of the membrane attack complex and reducing inflammatory cell activation.

Phase 2 pipeline (2)

• CSL300 · CSL Behring · Complement inhibitor · Immunology
  CSL300 is a recombinant human monoclonal antibody that targets the complement system.
• CSL_112 · CSL Behring · Complement inhibitor · Immunology
  CSL_112 is a recombinant human monoclonal antibody that targets the complement system.

Phase 1 pipeline (2)

• ALXN1210 IV · Alexion Pharmaceuticals, Inc. · Complement inhibitor · Rare Disease
  ALXN1210 is a C5 complement inhibitor that blocks the terminal complement cascade.
• ALXN1210 · Alexion Pharmaceuticals, Inc. · Complement inhibitor · Rare Disease
  Complement inhibitor